Meeting
2022 ASCO Annual Meeting
A phase I trial of T-cell receptor gene therapy targeting KK-LC-1 for gastric, breast, cervical, lung and other KK-LC-1 positive epithelial cancers.
Authors
Scott Norberg
National Cancer Institute, Bethesda, MD
Scott Norberg , Erika Maria Von Euw , Gordon Parry , Steven Highfill , Zulmarie Franco , James L. Gulley , Christian S. Hinrichs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT05035407
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2678)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2678
Abstract #
TPS2678
Poster Bd #
328a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase I/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers.
First Author: Christian S. Hinrichs
Poster
2024 ASCO Genitourinary Cancers Symposium
Final results of a phase I trial of HERV-E TCR transduced T cells for the treatment of HLA-A*11 patients with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Rosa Nadal
Poster
2023 ASCO Annual Meeting
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Rosa Nadal
Poster
2020 ASCO Virtual Scientific Program
KITE-439: A phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers.
First Author: Kedar Kirtane